Organogenesis said today that it launched its PuraPly Antimicrobial clinical research program, which will evaluate patients treated with PuraPly AM for up to 12 weeks. The 1st studies have started enrolling patients, according to Organogenesis.
The Canton, Mass.-based company’s PuraPly AM is a 510(k)-cleared device indicated for the management of acute and chronic wounds. The device is made of a bi-layered purified Type I collagen sheet, loaded with a broad spectrum antimicrobial agent that acts as a barrier against microbial colonization within wound dressings.
Get the full story at our sister site, Drug Delivery Business News.
The post Organogenesis launches PuraPly antimicrobial clinical program appeared first on MassDevice.
from MassDevice http://ift.tt/2n9R1fT
Cap comentari:
Publica un comentari a l'entrada